Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 dose

Venkatakrishnan K.Kim T.M.CHIA-CHI LINThye L.S.Chng W.J.Ma B.Chen M.H.Zhou X.Liu H.Kelly V.Kim W.S.2022-09-152022-09-1520150167-6997https://www.scopus.com/inward/record.uri?eid=2-s2.0-84944441520&doi=10.1007%2fs10637-015-0258-y&partnerID=40&md5=423c64425dae3d6902cdba99b14c9aaahttps://scholars.lib.ntu.edu.tw/handle/123456789/620302[SDGs]SDG3Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 dosejournal article10.1007/s10637-015-0258-y260849892-s2.0-84944441520